BIOC3 – Trademark Portfolio

Entity Type: 34

BIOC3 holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 2 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 1 trademark is registered and 1 is pending. Notable registered marks include BIOC3. The owner is based in F-31520 RAMONVILLE-SAINT-AGNE.

3 rue Ariane Bâtiment NAPA Center B

F-31520 RAMONVILLE-SAINT-AGNE , FR

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

FORGEN
FORGEN
Pending 2026
BIOC3
BIOC3
Registered 2019

Trademark Classifications

BIOC3's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (2 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

42
Computer & Scientific (2 filings)

Scientific and technological services; industrial analysis and research services

40
Treatment & Processing (1 filing)

Treatment of materials

Frequently Asked Questions

How many trademarks does BIOC3 have?

BIOC3 has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 pending.

What trademark classes does BIOC3 file in?

BIOC3 files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 40 (Treatment & Processing). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are BIOC3's most well-known trademarks?

BIOC3's registered trademark portfolio includes well-known marks such as BIOC3. These are among 1 currently registered trademark in the portfolio.

What is BIOC3's trademark registration success rate?

BIOC3 has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 1 application is pending review.